Kriya Therapeutics, Inc.

Kriya Therapeutics, Inc.

is a biopharmaceutical gene therapy company founded in 2019, headquartered in Palo Alto, California, with additional offices in Redwood City and Research Triangle Park, North Carolina. The company focuses on designing and developing one-time gene therapies for severe chronic diseases. Kriya operates as a fully integrated platform, aiming to enhance the speed and cost-effectiveness of gene therapy development and manufacturing. Kriya specializes in adeno-associated virus (AAV)-based gene therapies, utilizing two key technology platforms: SIRVE, which enables targeted vector design, and STRIPE, a high-efficiency manufacturing platform. The company's pipeline includes investigational gene therapy candidates for metabolic diseases, ophthalmology, and neurology, addressing conditions such as type 1 and type 2 diabetes, Geographic Atrophy, and Trigeminal Neuralgia. Kriya's mission is to provide innovative therapies for patients with significant unmet medical needs in the United States and beyond.